ArticleWorld journal of diabetes2024

Teneligliptin mitigates diabetic cardiomyopathy through inflammasome inhibition: Insights from experimental studies.

Chun-Yao Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.